首页> 美国卫生研究院文献>other >A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors

【2h】

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors

机译：DANUSERTIB（PHA-739358）的I次升级研究在晚期固体肿瘤患者的14天循环中施用为24小时输注和没有G-CSF

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the intravenous pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors.

著录项

期刊名称 other
作者
Roger B. Cohen; Suzanne F. Jones; Charu Aggarwal; Margaret von Mehren; Jonathan Cheng; David R. Spigel; F. Anthony Greco; Mariangela Mariani; Maurizio Rocchetti; Roberta Ceruti; Silvia Comis; Bernard Laffranchi; Jurgen Moll; Howard A. Burris;
展开▼
作者单位

展开▼
年(卷),期 -1(15),21
年度 -1
页码 6694–6701
总页数 21
原文格式 PDF
正文语种
中图分类
关键词
Danusertib PHA-739358 Aurora Kinase Inhibitor phase I trial solid tumors;

机译：Danusertib;PHA-739358;极光激酶抑制剂;I期试验;实体瘤;
入库时间 2022-08-21 11:29:37

相似文献

外文文献
中文文献
专利

1. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. [J] . Cohen RB, Jones SF, Aggarwal C Clinical cancer research: an official journal of the American Association for Cancer Research . 2009,第21期

机译：在晚期实体瘤患者中，在14天的周期内以24小时输注有和无粒细胞集落刺激因子的danusertib（PHA-739358）进行I期剂量递增研究。
2. 343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor [J] . H.A.Burris, G.Hudes, S.Jones, European Journal of Cancer Supplements . 2006,第12期

机译：晚期癌症/转移性实体瘤患者以极光激酶抑制剂PHA-739358的14周期周期为24天输注的343 POSTER I期剂量递增研究
3. 343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor [J] . H.A.Burris, G.Hudes, S.Jones, European Journal of Cancer Supplements . 2006,第12期

机译：晚期癌症/转移性实体瘤患者以极光激酶抑制剂PHA-739358的14周期周期为24天输注的343 POSTER I期剂量递增研究
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. An open-label dose-escalation safety and pharmacokinetics phase I study of ombrabulin a vascular disrupting agent administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors [O] . H. Murakami, T. Kurata, Y. Onozawa, -1

机译：一项开放性剂量递增安全性和药代动力学I期研究ombrabulin（一种血管破裂剂）每3周对日本晚期实体瘤患者进行30分钟静脉输注
7. A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors [O] . R. B. Cohen, S. F. Jones, C. Aggarwal, 2009

机译：DANUSERTIB（PHA-739358）的I剂量升级研究在晚期固体肿瘤患者的14天循环中施用24小时输注和没有粒细胞菌落刺激因子

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-hour Infusion With and Without G-CSF in a 14-day Cycle in Patients with Advanced Solid Tumors

摘要

著录项

相似文献

相关主题

期刊订阅